8-K current report · filed Nov 9, 2026

OCULAR THERAPEUTIX, INC (OCUL) 8-K Current Report: November 9, 2026

Item 5.02OCUL overview

Short answer

OCULAR THERAPEUTIX, INC (OCUL) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Riad Sherif, former Novartis and Alcon executive, elected to Class I board seat through 2027 annual meeting.

OCULAR THERAPEUTIX, INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Riad Sherif, former Novartis and Alcon executive, elected to Class I board seat through 2027 annual meeting
  • Ophthalmology industry expertise added through Oculis Holding AG CEO and Revenio Group board member
  • New director awarded option for 88,000 shares at $6.60 and restricted stock units for 28,000 shares
  • Equity awards vest annually over three years, creating potential dilution and aligning director incentives
  • Seung Suh Hong resigning effective December 31, 2026, without reported disagreement with management or the board

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other OCULAR THERAPEUTIX, INC 8-K filings

Get the next OCUL 8-K as it lands

Follow OCUL for push alerts, or ask the research agent what this filing means.